Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Psilocybin-assisted Cognitive Behavioral Therapy for Depression


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05227612

Organisation Name: University of California, Los Angeles

Overal Status: Not yet recruiting

Start Date: September 2022

Last Update: February 22, 2022

Lead Sponsor: University of California, Los Angeles

Brief Summary: The primary objectives of this clinical investigation are to (1) determine the feasibility of joining psilocybin treatment with CBT (cognitive-behavioral therapy) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) determine the initial efficacy of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. Psilocybin will be administered orally in two doses during the course of 12 sessions of CBT to eligible study participants - a 10mg dose following the third session and a 25mg dose following the sixth session. Participants will be in active treatment for the first 4 months (psilocybin + CBT) of the study and then followed for an additional 3-months following the termination of CBT.

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.24963688850403